Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The receptor activator of NF-kappaB (RANK) belongs to the neuregulin/tumor necrosis factor (TNF) receptor superfamily and is activated by RANK ligand (RANK-L), a homotrimeric, TNF-like cytokine. RANK is present on the surface of osteoclast cell precursors, where its interaction with RANK-L induces their terminal differentiation into osteoclasts, thus increasing bone breakdown. The secreted, soluble receptor osteoprotegerin (OPG) interrupts this activation by binding directly to RANK-L. Therefore, osteoclast maturation (and bone homeostasis) is regulated in vivo by OPG levels of expression. We have studied the assembly state and affinity of OPG for RANK-L by sedimentation analyses and surface plasmon resonance (Biacore). Full-length, homodimeric OPG binds to RANK-L with a KD of 10 nM. OPG is also a member of the TNF receptor superfamily and contains four disulfide-rich ligand-binding domains, yet lacks a transmembrane region separating the ligand-binding region from the two death domains, as observed for other receptor family members. We showed that dimerization of OPG results from noncovalent interactions mediated by the death domains and to a lesser extent by a C-terminal heparin-binding region. In contrast, a C-terminal intermolecular disulfide bond does not contribute to the formation or stability of OPG dimers. A truncate of osteoprotegerin, containing the ligand-binding domains but lacking the dimerization domains, bound RANK-L with a KD of approximately 3 microM, indicating that monomer oligomerization for the OPG provides an increase of 3 orders of magnitude in the affinity for RANK-L. Therefore, OPG dimer formation is required for the mechanism of inhibition of the RANK-L/RANK receptor interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability of OPG to suppress bone resorption and increase bone mass is related to its ability to bind via its TNF receptor domains to TNF domains within its natural ligand (17), now known as RANKL.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
In the citing paper
“to its target RANKL (17) and for osteoclast inhibition in cell culture studies (4,16).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
In the citing paper
“However, more recent analyses using analytical ultracentrifugation to more accurately identify monomer vs. homodimer forms revealed that the OPG homodimer had 1000-fold greater affinity for RANKL than the monomeric form (17).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. C. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181505 · Cited by 11,241
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Enhanced genome annotation using structural profiles in the program 3D-PSSM 1 1Edited by J. Thornton
Kelley, L. A., MacCallum, R. M., & Sternberg, M. J. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3741 · Cited by 1,468
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173
Research works printed but not linked: 2
- South-Paul, 2001, Am. Family Physician, 63, 897
- Carolino, 1998, Am. Family Physician, 57, 1293
Cited by
Items 101–121 of 121
The Variety of Osteocyte Function
O’Brien, C. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00006-2 · Cited by 1
Faulkner, M. G. (2011) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/2826159 · Cited by 2
“If both RANKL and OPG are released by the osteoblastic cell, then OPG binds to RANKL that effectively inhibits the osteoclastogenic activity of RANKL (Schneeweis et al., 2005).”
BackgroundMiyamoto, Y. (2014) · Journal of Oral Biosciences · doi:10.1016/j.job.2014.06.002 · Cited by 1
“Two OPG molecules form a dimer via a disulfide bridge between their C-terminal cysteine residues, which is required for binding to RANKL trimers [31].”
BackgroundElastase mediated-degradation of osteoprotegerin: Possible pitfalls and functional relevance
Nagy, E. E. (2020) · Bone · doi:10.1016/j.bone.2020.115256 · Cited by 1
On the Role of Osteoprotegerin/RANK/RANKL System in the Interaction between Prostate Cancer and Bone
Penno, H. (2011) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 3
Neumann, S. P. (2013) · OPUS Publication Server of the University of Stuttgart (University of Stuttgart) · doi:10.18419/opus-2151
Martins, G. M. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2013.tde-12062013-083322
Ashley, D. T. (2010) · Dublin City University Open Access Institutional Repository (Dublin City University)
Owen, S. (2014) · ORCA Online Research @Cardiff (Cardiff University)
Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène
Lamoureux, F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Dawson, S. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Immune mechanisms behind plaque vulnerability: experimental and clinical studies
Овчинникова, О. А. (2010) · Figshare
Rôle du récepteur RANK dans la régulation du métabolisme énergétique hépatique et adipocytaire
Phan, F. (2022) · theses.fr (ABES) · doi:10.70675/009ba81az6addz47b3z9e33zcc6ad1543dcb
Kas İskelet Sistemi ve Kemik Sağlığı
Aslan, Y., Şimşek, M., Yılmaz, M., Harmancı, H., Savaş, S., Polat, C., Ünveren, A., Yılmaz, B., Kilit, T. P., Torun, M. T., et al. (2024) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3293
in vitro and in vivo Osteoprotegerin increases leukocyte adhesion to endothelial cells both
Tedesco, F., Secchiero, P., Zauli, G., Corallini, F., Bossi, F., Fabio Fischetti, I., Durigutto, P., & Celeghini, C. (2013)
Homéogènes Dlx, signalisation RANK/RANKL et ostéosarcomes
Navet, B. (2016) · theses.fr (ABES) · doi:10.70675/9f9d3d45zb9e6z496dz8aa6z8b9e2722f757
Gomes, J. I. S., Abreu, A. P. D. A., Costa, J. M., Cunha, A. P. A., Reis, D. R. A., Sousa, F. V., Ávila, E. P. N., Corrêa, R. D. G. C. F., Calixto, J. D. R. R., CABRAL, F. C. B. V., et al. (2025) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.rmrp.2025.227715
Research Progress on Mechanisms and Pharmacological Interventions of Coronary Artery Calcification
Wang, Y., & Duan, N. (2026) · Angiology · doi:10.1177/00033197261492091
Metadata
- Authors
- Schneeweis, L. A., Willard, D., & Milla, M. E.
- Affiliations
- University of Pennsylvania (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Schneeweis, Lumelle A.
- Milla, Marcos E.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 280
- Issue
- 50
- Pages
- 41155-41164
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2000736649
- Cited by
- 116
- References
- 35
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5418 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r21dk067831-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK067831)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- osteoprotegerin, RANK ligand, RANK, TNF receptor superfamily, receptor dimerization, ligand binding affinity, death domain, disulfide bonds, osteoclastogenesis, bone homeostasis
- MeSH terms
- Animals, Antibody Affinity, Biological Assay, Carrier Proteins, Cell Differentiation, Cell Membrane, Circular Dichroism, Disulfides, Escherichia coli, Genetic Vectors, Glycoproteins, Heparin, Humans, Insecta, Kinetics, Ligands, Membrane Glycoproteins, Models, Chemical, Mutation, Osteoclasts, Protein Binding, Proteins, Time Factors, Viruses, Cytokines, Protein Structure, Tertiary, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Dimerization, Surface Plasmon Resonance, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.